Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome
- PMID: 8984701
- PMCID: PMC472613
- DOI: 10.1136/thx.51.9.907
Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome
Abstract
Background: Early postnatal use of dexamethasone in infants with respiratory distress syndrome (RDS) has been shown effectively to improve pulmonary status and to allow early weaning off mechanical ventilation. However, the mechanisms to explain the beneficial effects of dexamethasone in ventilatory dependent preterm infants remain unclear.
Methods: A double blind, placebo controlled study was performed to determine the change in pulmonary ventilation of premature infants with RDS as a result of dexamethasone treatment, and to evaluate the effect of dexamethasone on the levels of surfactant-associated proteins A (SP-A) and D (SP-D) in the tracheal fluid from 34 premature infants with RDS and 29 control subjects.
Results: Dexamethasone treatment decreased fractional inspired oxygen concentration (FIO2), arterial carbon dioxide tension (PCO2), mean airway pressure (MAP), and facilitated successful weaning from mechanical ventilation. SP-A concentrations in the tracheal aspirates were increased at days 7 and 14, and SP-D concentrations were increased during the period from days 3 to 14 in the dexamethasone treated group compared with the control group. However, albumin levels in the tracheal aspirate samples were decreased after dexamethasone treatment over the period from days 3 to 14. There was an inverse correlation between PCO2 values and SP-A concentrations.
Conclusions: These results suggest that early use of dexamethasone can improve pulmonary status and also increase SP-A and SP-D levels in the tracheal fluid in premature infants with RDS.
Comment in
-
Steroids, surfactant and lung disease.Thorax. 1996 Sep;51(9):880-1. doi: 10.1136/thx.51.9.880. Thorax. 1996. PMID: 8984696 Free PMC article. No abstract available.
Similar articles
-
Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome.Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1672-7. doi: 10.1164/ajrccm.150.6.7952631. Am J Respir Crit Care Med. 1994. PMID: 7952631
-
Surfactant apoprotein A (SP-A) in tracheal aspirates of newborn infants with RDS.Acta Paediatr Jpn. 1991 Oct;33(5):649-54. doi: 10.1111/j.1442-200x.1991.tb01880.x. Acta Paediatr Jpn. 1991. PMID: 1799120
-
Surfactant proteins and stable microbubbles in tracheal aspirates of infants with respiratory distress syndrome: relation to the degree of respiratory failure and response to exogenous surfactant.Eur J Pediatr. 1997 Feb;156(2):131-8. doi: 10.1007/s004310050571. Eur J Pediatr. 1997. PMID: 9039518
-
Choosing a right surfactant for respiratory distress syndrome treatment.Neonatology. 2009;95(1):1-5. doi: 10.1159/000151749. Epub 2008 Oct 2. Neonatology. 2009. PMID: 18832858 Review.
-
Inherited disorders of neonatal lung diseases.Turk J Pediatr. 2004 Apr-Jun;46(2):105-14. Turk J Pediatr. 2004. PMID: 15214737 Review.
Cited by
-
Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study.Respir Res. 2008 Jan 28;9(1):13. doi: 10.1186/1465-9921-9-13. Respir Res. 2008. PMID: 18226251 Free PMC article. Clinical Trial.
-
Effects of antenatal and postnatal corticosteroids on the preterm lung.Arch Dis Child Fetal Neonatal Ed. 1997 Sep;77(2):F147-50. doi: 10.1136/fn.77.2.f147. Arch Dis Child Fetal Neonatal Ed. 1997. PMID: 9377142 Free PMC article. Review. No abstract available.
-
The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.Arch Dis Child. 2003 Nov;88(11):981-4. doi: 10.1136/adc.88.11.981. Arch Dis Child. 2003. PMID: 14612363 Free PMC article. Review.
-
Surfactant Protein D in Respiratory and Non-Respiratory Diseases.Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29473039 Free PMC article. Review.
-
Current and Emerging Therapies for Prevention and Treatment of Bronchopulmonary Dysplasia in Preterm Infants.Paediatr Drugs. 2025 May 15. doi: 10.1007/s40272-025-00697-3. Online ahead of print. Paediatr Drugs. 2025. PMID: 40374983
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical